DUSP2 and breast carcinoma: Moreover, hypoxia/HIF1α induces lapatinib resistance in HER2-positive breast cancer cells via regulation of DUSP2 and HIF-1 can bypass the lapatinib-treated inhibition of the ERK pathway via inhibition of the dual-specificity phosphatase 2 (DUSP2).